EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Incorporating a Shortened Long-Term Effectiveness End Point Into Catheter Ablation Trials: Statistical Properties and Implications

Jason G Andrade iD, Stephen Hynes, Farid Jamshidian iD, Andrea Natale iD

Circulation: Arrhythmia and Electrophysiology · 2026-10 · 19 (10)

DOI: 10.1161/circep.125.014773 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Circulation: Arrhythmia and Electrophysiology, 2026-10. Verfasst von Jason G Andrade und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Vancouver General Hospital, Vancouver, Canada (J.G.A.). Hauptthemen laut MEDLINE: Atrial Fibrillation, Catheter Ablation, Endpoint Determination, Clinical Trials as Topic. Die Arbeit nennt 8 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Evidence regarding the use of a 6-month effectiveness end point for trials of atrial fibrillation ablation is limited. This study aims to evaluate the relationship between ablation effectiveness end point detection and follow-up duration, with the secondary goal of informing the design of clinical trials of paroxysmal atrial fibrillation ablation. METHODS: Patient-level data from 4 prospective studies were aggregated. Long-term effectiveness end points were calculated with (1) a 3-month blanking period and 12-month follow-up (current) and (2) a 2-month blanking period and 6-month follow-up (proposed). Sensitivity, specificity, and agreement were calculated for each study under the current and proposed end points. A linear approximation method was used to extrapolate the 6-month survival estimate to 12 months, and the predicted 12-month survival rates were compared with the actual 12-month survival rates. Using the linear approximation, a new performance goal was derived and compared against the 6-month survival of each study. RESULTS: The comparative analysis between the current and proposed end points demonstrated concordances ranging from 83% to 92% and sensitivities ranging from 57% to 76% across the 4 recent clinical trials. The linear approximation method produced an estimated 12-month survival rate of the 4 pooled studies of 72.5%, compared with the true 12-month survival rate of 71.0% (−1.5% error). When compared against the true 12-month survival rate in each study individually, the estimated 12-month survival rate resulted in errors ranging from −3.6% to 0.3%. A new performance goal of 56.2% is proposed for trials using a 6-month end point. CONCLUSIONS: The proposed end point of a 6-month follow-up duration, inclusive of a 2-month blanking period, demonstrated reasonable levels of agreement with the current 12-month effectiveness end point. Enabling historical comparison, a 12-month survival rate can be reliably extrapolated from a 6-month survival rate using linear approximation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Atrial FibrillationCatheter AblationEndpoint DeterminationClinical Trials as TopicHumansTreatment OutcomeTime FactorsProspective Studies

Stichwörter der Autor:innen

atrial fibrillationatrial fluttercatheter ablationclinical trialsurvival rate

Autor:innen und Institutionen

  • Department of Medicine, Vancouver General Hospital, Vancouver, Canada (J.G.A.).
  • Center for Cardiovascular Innovation, Vancouver, Canada (J.G.A.).
  • Department of Medicine, Montréal Heart Institute, Université de Montréal, Montréal, Canada (J.G.A.).
  • Biosense Webster, Inc., part of Johnson & Johnson MedTech, Irvine, CA (S.H., F.J.).
  • Texas Cardiac Arrhythmia Research Foundation, Austin, TX (A.N.).
  • Division of Cardiology, Department of Biomedicine and Prevention, University of Tor Vergata, Rome, Italy (A.N.).

ORCID-Profile: Jason G Andrade, Farid Jamshidian, Andrea Natale

Zitieren

APA

Andrade, J. G., Hynes, S., Jamshidian, F., & Natale, A. (2026). Incorporating a Shortened Long-Term Effectiveness End Point Into Catheter Ablation Trials: Statistical Properties and Implications. Circulation: Arrhythmia and Electrophysiology, 19(10). https://doi.org/10.1161/circep.125.014773

Vancouver

Andrade JG, Hynes S, Jamshidian F, Natale A. Incorporating a Shortened Long-Term Effectiveness End Point Into Catheter Ablation Trials: Statistical Properties and Implications. Circulation: Arrhythmia and Electrophysiology. 2026;19(10). doi:10.1161/circep.125.014773

BibTeX
@article{Andrade2026,
  author = {Andrade, Jason G and Hynes, Stephen and Jamshidian, Farid and Natale, Andrea},
  title = {Incorporating a Shortened Long-Term Effectiveness End Point Into Catheter Ablation Trials: Statistical Properties and Implications},
  journal = {Circulation: Arrhythmia and Electrophysiology},
  year = {2026},
  volume = {19},
  number = {10},
  doi = {10.1161/circep.125.014773}
}
Kostenlos starten →